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Rationale: Myxomatous mitral valve degeneration is a common pathological
manifestation of mitral valve regurgitation, with or without valvular prolapse.
In addition to similarities between naturally occurring and serotonergic valve
degeneration, an increasing body of evidence has recently suggested that
serotonin signaling is a regulator of degenerative valvulopathies. Studies have
found that serotonin can be synthesized locally by valvular cells and serotonin
receptors in turn may be activated to promote signaling. Recently, telotristat
ethyl (TE) has been introduced as a treatment for carcinoid disease, by
selectively inhibiting tryptophan hydroxylase 1, the rate-limiting enzyme in
peripheral serotonin synthesis. TE provides a unique tool to test inhibition
of serotonin synthesis in vivo, without impacting brain serotonin, to further
confirm the role of local serotonin synthesis on heart valves.
Objective: To confirm the link between serotonin and myxomatous valvular
disease in vivo.
Methods and results: A hypertension-induced myxomatous mitral valve
disease mouse model was employed to test the effect of TE on valvular
degeneration. Circulating serotonin and local serotonin in valve tissues were
tested by enzyme immunoassay and immunohistochemistry, respectively.
TE was administrated in two modes: (1) parallel with angiotensin II (A2);
(2) post A2 treatment. Myxomatous changes were successfully recapitulated
in hypertensive mice, as determined by ECM remodeling, myofibroblast
transformation, and serotonin signaling activation. These changes were at
least partially reversed upon TE administration.
Conclusion: This study provides the first evidence of TE as a potential
therapeutic for myxomatous mitral disease, either used to prevent or reverse
myxomatous degeneration.
KEYWORDS

telotristat ethyl, serotonin, hypertension, myxomatous mitral disease, mouse model
Abbreviations: TE, telotristat ethyl; ECM, extracellular matrix; VIC, valvular interstitial cell; α-SMA,
alpha-smooth muscle actin; MMP1, matrix metalloproteinase 1; TGFβ1, transforming growth
factor beta 1; TPH1, tryptophan hydroxylase 1; 5HTR2b, serotonin receptor type 2B; IHC,
immunohistochemistry; SBP, systolic blood pressure; Sal, saline; SalTE; combination of saline and
telotristat ethyl; A2, angiotensin II; A2TE, combination of angiotensin II and telotristat ethyl.
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Introduction

increased in myxomatous mitral valves, while serotonin
transporter was decreased leading its reduced metabolism (16).
However, it is still unclear how serotonin circulating in plasma
and serum triggers and/or mediates myxomatous mitral disease
(17–19). In addition to evidence from ex vivo myxomatous
mitral valves, other in vitro studies have shown that local
serotonin in mitral valves can be induced by mechanical stimuli
and regulates myxomatous proteins (20, 21).
However, in vivo studies to substantiate the role of serotonin
regulation on valvulopathies are missing due to the lack of
selectivity of TPH1 inhibitors. Recently, telotristat ethyl (TE) has
been released for the treatment of carcinoid syndrome. TE is a
specific TPH1 inhibitor (22), which does not cross the bloodbrain barrier, thus not interfering with serotonin in the brain,
synthesized by TPH2. Based on clinical evidence suggesting
that TE works effectively to inhibit serotonin synthesis in the
gut (22), we expect it to function as an effective inhibitor of
serotonin synthesis by heart valves. Thus, here we hypothesized
that serotonin synthesis inhibition ameliorates the severity
of myxomatous mitral valve disease in hypertensive mice.
To test this hypothesis, mice were rendered hypertensive by
subcutaneous angiotensin II (A2) delivery with or without
TE administration, and parallel groups of normotensive mice
served as controls. By studying this mouse model, we aimed to:
(1) confirm that mitral myxomatous changes can be induced in
hypertensive mice that received a short-term A2 administration;
(2) demonstrate that myxomatous changes and high blood
pressure correlate with high serotonin; (3) validate the role of TE
on myxomatous mitral valves in hypertensive mice; 4) elucidate
the link between serotonin and myxomatous valvular disease
in vivo.

The most common mitral valve disorder is mitral
regurgitation, often with myxomatous degeneration as the
dominant pathology (1). According to the most current
Heart Disease and Stroke Statistics update, the prevalence
of myxomatous mitral disease is greater than 1.5% in the
United States population and dramatically increases with
age (1). At the macroscopic level, myxomatous mitral valve
leaflets are typically elongated and distorted, leading to
prolapse and improper coaptation (2). At the microscopic level,
myxomatous mitral valves undergo extracellular matrix (ECM)
remodeling and valvular interstitial cell (VIC) phenotype
transformation (3).
Valvular homeostasis is maintained by quiescent VICs, the
main cell population in normal heart valves (3, 4). In naturally
occurring myxomatous mitral valve disease, accompanied or
not by valve regurgitation and prolapse, quiescent VICs
are transformed to activated VICs, which exhibit increased
cell proliferation and enhanced expression of myofibroblastic
protein markers, such as alpha-smooth muscle actin (α-SMA),
matrix metalloproteinase 1 (MMP1), and transforming growth
factor beta 1 (TGFβ1) (3, 5, 6). In addition, ECM remodeling
occurs due to increased expression of matrix metalloproteinases
(MMPs) and tissue inhibitors of MMPs, collagen degradation,
proteoglycan accumulation, and elastin fiber fragmentation (3,
4). Similarly in carcinoid heart disease, patients of carcinoid
syndrome develop right heart failure as right-sided heart
valves develop a similar pathology (7, 8). The outflow side
of the tricuspid and pulmonary valves are known to develop
carcinoid plaques, largely composed of highly proliferative
myofibroblastic VICs (activated VICs), deposited myxoid ECM
rich in collagen and proteoglycans, which together result in
valvular regurgitation (9, 10). Carcinoid plaques form more
rarely on the left side due to the pulmonary circulation
clearing serotonin from arterial blood, which contacts mitral
and aortic valves. Despite the differences in location, the cell
and molecular changes occurring in myxomatous mitral valve
disease and in carcinoid heart disease are evidently similar
(8). To further solidify these commonalities, serotonergic valve
disease has been found to be inducible by serotonin directly
in a murine model (11) or in humans undergoing the FenPhen diet, a combination of anorexigen drugs that increase
circulating serotonin (fenfluramine and phentermine are both
potent inhibitors of serotonin uptake) (12, 13). At the molecular
level, serotonergic valve disease is similar to the cases described
above, which culminates in potential valve failure (14).
Based on the evidence described above, it has now
been demonstrated that serotonin is locally synthesized by
mitral valves and regulates myxomatous pathology. Tryptophan
hydroxylase 1 (TPH1), the rate-limiting enzyme for peripheral
serotonin synthesis, was intensively expressed in myxomatous
human and canine mitral valves (15). Additionally, serotonin
receptor type 2B (5HTR2b), in company with TPH1, was
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Materials and methods
Animals
Wild-type, 6-week old C57BL6J mice of both genders
were purchased from Jackson Laboratory (Bar Harbor, ME,
United States). Male and female mice were housed separately
and maintained under standard conditions within Animal Care
Service Facility at Texas Tech University (TTU). Mice in groups
of two per cage were maintained under an artificial 12-h darklight cycle. They were allowed free access to food and water
and were acclimated for five. All animal experiments followed
TTU Institutional Animal Care and Use Committee (IACUC)
approved protocol number T18006.

ALZET pump preparation
Mini-osmotic pumps, models 2004 or 2006 (both from
ALZET, Cupertino, CA, United States) with delivery duration
of 4 or 6 weeks respectively, were employed for delivery of A2
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To finalize the surgery procedure, each incision was closed with
two 7-mm Reflex wound closure clips (Harvard Apparatus,
Holliston, MA, United States). After the surgery, each mouse
was transferred to a cage with a clean towel in and a heat pad
under to prevent hypothermia and allowed to wake up. All
mice were weighed and tattooed on the tail for identification
purposes. After surgery, mice were transferred to a new cage
and housed in pairs. Mice were maintained under standard
conditions at TTU Animal Care Service Facility for 4 or 6 weeks.

or saline. Osmotic pumps were preloaded and primed under
sterile conditions following the protocol from the manufacturer.
Loading solutions were sterile A2 (Millipore Sigma, Burlington,
MA, United States) in 0.9% (w/v) saline (Fisher Scientific,
Hampton, NH, United States) or sterile 0.9% saline (Sal). Preloaded pumps were primed in sterile 0.9% saline in an incubator
at 37◦ C for at least 40 or 60 h depending on pump model,
prior to subcutaneous implantation. In study 1 – prevention
mode, mini-osmotic pumps model 2004 filled with A2 delivered
1 µg/kg/min at a flow rate of 0.25 µL/h to achieve 0.8 mg of A2
total per 20 g animal for period of 4 weeks. In study 2 – reversal
mode, mini-osmotic pumps model 2006 filled with A2 delivered
1 µg/kg/min at a flow rate of 0.15 µL/h to achieve 1.2 mg of A2
total per 20 g animal for a period of 6 weeks.

Inducing myxomatous changes and
their reversal
Two studies were performed separately and animals were
divided into 4 groups (Sal, A2, SalTE, A2TE) in each study. In
the first study – prevention mode, ALZET model 2004 pumps
preloaded with A2 or saline vehicle (A2 negative control) were
surgically implanted into 100 mice (50 males and 50 females)
with or without TE administration in parallel for 4 weeks.
Briefly, TE was administered daily as described below as the
pumps delivered 1 µg/kg/min saline or A2 for 28 days to each
animal in pertinent groups. In the second study – reversal mode,
ALZET pumps model 2004 or 2006 preloaded with A2 or saline
vehicle (A2 negative control) were surgically implanted into 100
mice (50 males and 50 females). Mice implanted with model
2006 pumps received 1 µg/kg/min saline or A2 for 42 days. Mice
implanted with model 2004 pumps received 1 µg/kg/min saline
or A2 for 28 days followed by a late administration of TE in
the last 2 weeks, to reverse previously developed myxomatous
changes. Complete experimental details of these two studies are
summarized in Table 1.
Telotristat ethyl was provided by Lexicon Pharmaceuticals
(Basking Ridge, NJ, United States). TE was prepared as a
suspension in 0.25 % (w/v) methylcellulose (Spectrum, New
Brunswick, NJ, United States) to a final concentration of
0.24 g/mL TE. Each mouse was fed 25 µL TE solution once each
day by oral gavage to achieve 300 mg/kg/day, a dose at which

Subcutaneous pump implantation
surgery
Right after acclimation, mice underwent implantation of
subcutaneous mini-osmotic pumps. Anesthesia chamber was
pre-filled with 4% isoflurane (Patterson Veterinary, Greeley,
CO, United States) with 2 L/min oxygen flow. After mouse was
transferred into chamber, isoflurane was reduced to 2%, and
mouse was transferred to a nose cone in ventral recumbence.
Eyes were covered by ophthalmic lubricant ointment. Slow
release SR Buprenorphine (Wildlife Pharmaceuticals, Windsor,
CO, United States) at dose 0.05 mg/kg was administered preemptively via injection to control pain for 72 h. The skin
between the shoulder to the mid-back was shaved and aseptically
wiped with 70% alcohol and 4% chlorhexidine gauze sponges
for 4 times. Subsequently, animal was immediately transferred
to a clean procedural table with a heat pad underneath and
covered by a sterile disposable towel. A mid-scapular incision
(∼ 10 mm) was made by a sterile blade to open the dorsal
skin, and a subcutaneous pocket was created by inserting sterile
scissors to fit mini-osmotic pumps. A mini-osmotic pump prefilled with A2 or saline vehicle was implanted into the pocket.
TABLE 1 Experimental design.

Study

Group

Experimental
period

Mini-osmotic
pump model

Loading
solution

Number of Mice

Male
Prevention

Sal

4 weeks

Total

2004

Sal

14

10

24

Not Applied

2004

Sal

10

16

26

Applied for 4 weeks

A2

2004

A2

14

10

24

Not Applied

A2TE

2004

A2

12

14

26

Applied for 4 weeks

SalTE

Reversal

Female

TE administration

2006

Sal

12

12

24

Not Applied

SalTE

Sal

6 weeks

2004

Sal

10

14

24

Applied in the last 2 weeks

A2

2006

A2

14

12

26

Not Applied

A2TE

2004

A2

14

12

26

Applied in the last 2 weeks
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blood samples were centrifuged, then precipitated in 9 volumes
of ethanol at −80◦ C overnight to remove hemoglobin and other
proteins after complete cell lysis (23). Serotonin was enriched
in the supernatant ethanol layer and vacuum concentrated.
Enzyme-linked immunosorbent assay was performed following
the manufacturer’s protocol. The average and standard deviation
in each group were calculated from eight biological replicates.
Statistical differences on circulating serotonin among treatments
were assessed by multiple comparison tests following one-way
ANOVA, and p < 0.05 were considered significant.

dose peripheral serotonin was significantly reduced in mice guts,
without inducing side effects.2 TE was administered either in
parallel or post-A2 treatment until the day before euthanasia.

Blood pressure in vivo measurement
Blood pressure measurements were conducted using the
CODA non-invasive blood pressure system (Kent Scientific,
Torrington, CT, United States) every 4 days over the complete
experimental period. The procedure followed the owner’s
manual from Kent Scientific. A CODA controller was connected
to a laptop installed with CODA software (CODA 4.1), and
a warming platform was preset to 38 o C. After mice were
properly placed in pre-warmed holders, their tails entered
the CODA cuff assembly with the occlusion cuff close to tail
base and the volume pressure recording (VPR) sensor distal
to the O-cuff. Both O-cuff and VPR sensor were connected
to the CODA controller. Data tables were created by the
system containing systolic, diastolic, and mean blood pressures.
Statistical differences on blood pressure among treatments
were assessed by multiple comparison tests following one-way
ANOVA and p < 0.05 were considered significant.

Histology and histological staining
Histological slide preparation
Mouse hearts were symmetrically bisected across the center
of the ventricles. After fixation in formaldehyde, dehydration,
clearing and paraffin infiltration, heart sections were paraffinembedded in tissue cassettes with left ventricles next to each
other. Tissue-embedded paraffin blocks were sliced into 4 µm
slices by a rotary microtome and slices placed onto poly-L-lysine
coated glass slides (Fisher Scientific). Sections were air dried
overnight prior to deparaffinization in xylenes and subsequent
rehydration prior to staining.

Exsanguination and heart collection

Modified russell-movat pentachrome stain
Mitral valve sections were stained by a Movat-Russell
modified pentachrome stain kit (American MasterTech, Lodi,
CA, United States). The staining procedure followed the
protocol recommended by the manufacturer. Elastic fibers
and nuclei were stained black and dark purple, respectively.
Polysaccharides, muscle and collagen were stained in sequence
by alcian blue, the combination of crocein scarlet and acidic
fuchsine, and alcoholic saffron in greenish blue, red, and
yellow, respectively. Sections were allowed to air dry and
mounted with Permount mounting medium (Fisher Scientific)
and cover glasses. Bright-field images were acquired using
a color camera (DFC295) of Leica DMI6000 B microsystem
(Leica Microsystems, Buffalo Grove, IL, United States). Valve
thicknesses were measured at the base of the leaflets on
histological sections using a scale bar in LAS X microscope
software (Leica Microsystems). Average values and standard
deviations of thickness measurement were calculated from 26
images from at least 6 biological replicates. Statistical differences
on valve thickness among treatments were assessed by multiple
comparison tests following one-way ANOVA, and p < 0.05 were
considered significant.

At the end of in vivo treatments (4 or 6 weeks), mice
underwent carbon dioxide asphyxiation. After mice ceased
breathing, they were weighed and transferred to an operation
bench. The death was confirmed by cervical dislocation.
Subsequently, blood was collected through the abdominal
aorta and hearts were collected through a thoracic incision.
Blood samples were immediately supplemented with 0.1%
ethylenediaminetetraacetic acid (Fisher Scientific) and stored
at −20◦ C for future serotonin enzyme-linked immunosorbent
assay. Hearts were washed at least 3 times in phosphatebuffered saline [PBS, 137 mM sodium chloride, 2.7 mM
potassium chloride, 4.3 mM sodium phosphate dibasic and
1.46 mM potassium phosphate monobasic (all from Fisher
Scientific)] supplemented with 0.1% ethylenediaminetetraacetic
acid, followed by fixation in 4% formaldehyde (Fisher Scientific).
Paired Student’s t-test was performed to assess the significant
differences on animal weight changes with age. P < 0.05 were
considered significant.

Circulating serotonin quantification
Immunohistochemistry
To investigate differences in expression of protein
markers on mitral valves receiving different treatments,
Immunohistochemistry (IHC) was performed using a
commercial ready-to-use kit (BioVision, Milpitas, CA,

The total concentration of serotonin circulating in blood
was determined by serotonin isolation from blood proteins
followed by a serotonin enzyme-linked immunosorbent assay
(Enzo Life Science, Farmingdale, NY, United States). Briefly,

Frontiers in Cardiovascular Medicine

04

frontiersin.org

Wang et al.

10.3389/fcvm.2022.945672

with no significant differences observed across treatments
(Supplementary Figures 1A,B).
In both prevention and reversal studies, blood pressure
baseline was measured from 100 animals the day before
surgeries, and animals were all normotensive initially
(Figures 1A,B). Blood pressure baselines in reversal study
were higher than those from prevention study, due to a different
size of occlusion cuff used in reversal study. In both cases,
there was no significant difference on blood pressure baseline
between males and females, as shown on Figures 1A,B.

United States). The protocol provided by the manufacturer
was followed. First, peroxidase block was applied to tissue
sections for 10 min. After 10 s wash in water, sections were
immersed in pre-boiled sodium citrate buffer (10 mM sodium
citrate, 0.05% Tween 20 (both from Fisher Scientific), pH 6.0)
and immediately transferred to a pre-heated steamer. The
requirement of heat-induced antigen retrieval step depended
on the primary antibody applied later. In this study, antigen
retrieval was employed in the staining of 5HTR2b, TGFβ1,
and MMP1. Sections were then cooled in cold water and
incubated with protein blocking solution for 10 min. Primary
antibodies were applied to tissue sections and incubated for
30–60 min without drying. Primary antibodies employed were
mouse monoclonal anti-TPH (Millipore Sigma) at a final
concentration of 2 µg/mL, mouse monoclonal anti-smooth
muscle actin (Fisher Scientific) at a final concentration of
1.25 µg/mL, rabbit polyclonal anti-5HTR2b (Novus Biologicals,
Centennial, CO, United States) at a final concentration of
2.4 µg/mL, rabbit polyclonal anti-TGFβ1 (Abcam, Cambridge,
United Kingdom) at a final concentration of 5 µg/mL,
rabbit polyclonal anti-MMP1 (Invitrogen, Carlsbad, CA,
United States) at a final concentration of 0.92 µg/mL. After
primary antibody binding, another 30-min incubation with
HRP polymer was performed, followed by washes in PBS
and water in sequence. Positive expression of proteins was
visualized in a dark brown color after a 10 min reaction with
diaminobenzidine chromogen. Lastly, nuclei were labeled by
hematoxylin (Electron Microscopy Sciences, Hatfield, PA,
United States) in dark purple, and sections were washed in
water for 20 min for better coloration. Sections were mounted
with Fluoromount-G hydrophilic mounting medium (Southern
Biotech, Birmingham, AL, United States) and cover glasses
after air drying. Bright-field images were acquired as above.
For the quantitative evaluation of each protein marker, at
least 4 biological replicates in each treatment group were
tested. Protein expression was quantified in MATLAB R2018b
(MathWorks, Natick, MA, United States), where the total
stained area in pixels was measured from at least 4 biological
replicates after background and noise were removed by
thresholding. Significant differences in protein expression were
assessed by Kruskal-Wallis and multiple comparison tests.
P < 0.05 were considered significant.

Hypertension was successfully induced
by subcutaneous angiotensin II
delivery in mice
Systolic, diastolic and mean blood pressures of each animal
were measured every 4 days over the entire experimental periods
of both studies. Since paired systolic, diastolic and mean blood
pressures showed the same trends, only systolic blood pressures
(SBP) are reported here and were used to assess differences
across treatments.
In the prevention study, SBPs from Sal and SalTE
groups overlaid throughout the entire experimental period,
and were much lower than SBPs from A2-treated groups on
each measurement date (Figure 2A). However, the parallel
administration of A2TE ceased the increase in blood pressure
after day 21. This demonstrates that A2 dramatically elevated
blood pressure from 149.6 35.6 mmHg to 203.8 34.6 mmHg
in mice, and sustained TE administration seemed to reverse A2induced hypertension, as indicated by a less increase in blood
pressure from 142.7 32.2 mmHg to 185.8 36.7 mmHg in
4 weeks. To further evaluate the effects of A2 and/or TE on
blood pressure, blood pressures from final measurements were
compared across treatments, as shown in Figure 2B. Final day
blood pressures from angiotensin groups (A2 and A2TE) were
significantly higher than those from saline groups (Sal and
SalTE). Moreover, TE decreased blood pressure in A2TE but
not SalTE. The main findings are 1) A2 significantly induced
hypertension in mice within 4 weeks; 2) TE reversed A2-induced
hypertension in mice, without effects in normotensive mice.
In the reversal study, TE was administered in the last
2 weeks of the total 6 weeks of A2 treatment. Consistently
with the observations from the prevention study, A2 largely
induced high blood pressure from 153.9
37.0 mmHg to
178.4 42.6 mmHg, which was reversed by TE supplementation,
where blood pressure was elevated from 150.2 32.0 mmHg
to 164.9 28.8 mmHg (Figure 3A). On the other hand, TE
administration did not result in differences in blood pressure
among saline groups (Figure 3A). Again, endpoint blood
pressures before and after TE administration (Day 29 and Day
41) were compared across treatments. Before TE administration
(Day 29), blood pressures in angiotensin groups (A2 and A2TE)

Results
All mice were initially normotensive
In the prevention study, average weights of animals
increased from 21.5
3.5 g to 22.6
3.7 g in 4 weeks,
while in the reversal study, average weights increased from
22.0
2.8 g to 25.0
3.2 g in 6 weeks. In both cases,
weights of males were always higher than those of females,
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FIGURE 1

Blood pressure baseline in prevention (A) and reversal (B) studies.

FIGURE 2

(A) Systolic blood pressure changes with time in hypertensive and normotensive mice in prevention study. (B) Endpoint (Day 29) systolic blood
pressure comparison across treatments. Asterisk indicates significant difference (p < 0.05).

were significantly higher than those from saline groups (Sal and
SalTE) (Figure 3B). After 2 weeks along with TE administration
(Day 41), blood pressure was continuously increased by A2, but

Frontiers in Cardiovascular Medicine

this change was prevented by TE (Figure 3B). However, TE
administration did not cause a change in saline group (SalTE).
By the end of the experiment, blood pressures from A2 group
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FIGURE 3

(A) Systolic blood pressure changes with time in hypertensive and normotensive mice in reversal study. (B) Endpoint (Day 29 and 41) systolic
blood pressure comparison across treatments. Asterisk indicates significant difference (p < 0.05).

were significantly higher than those from the other 3 groups,
indicating an impact of TE on A2-induced high blood pressure.
These findings demonstrate that A2 continuously increased
blood pressure in mice for 6 weeks, but the resulting high
blood pressure was significantly reversed by TE administration.
Data from both studies suggested that A2 successfully induced
hypertension in mice and TE counteracted this effect in either
parallel or late administration.

in hypertensive mice, with average levels of 1838.82 and
690.33 ng/mL, respectively.
Similar results of circulating serotonin concentrations
were observed in reversal study, where TE was administered
following the treatment with A2 or Sal. A2 reduced circulating
serotonin after 6 weeks (Figure 4B), although not significantly.
The 2-week administration of TE significantly reduced
serotonin levels in blood compared to those in corresponding
Sal and A2 (Figure 4B). Moreover, the lowest concentration of
serotonin appeared in A2TE as before (Figure 4B). These data
suggested that longer A2 treatment slightly reduced serotonin
level, while TE always effectively inhibited circulating serotonin.
Moreover, this inhibitory effect was maximized in combination
with A2. Circulating serotonin was reduced by TE from 2497.15
to 1634.61 ng/mL in normotensive mice and from 1978.64
to 1016.05 ng/mL in hypertensive mice, resulting 34.54 and
48.65% reductions, respectively.

Angiotensin II and telotristat ethyl
synergistically reduce circulating
serotonin in mice
Circulating serotonin levels were compared across
treatments. In the prevention study, A2 significantly
reduced circulating serotonin in mice, compared to Sal
group that served as normotensive control (Figure 4A).
Concentrations of circulating serotonin in TE-treated mice
were significantly lower than those in the corresponding
Sal or A2 groups (Figure 4A), as expected. However,
the inhibitory effect of TE on serotonin was higher in
the presence of A2 (Figure 4A). TE reduced circulating
serotonin from 2952.51 to 1862.00 ng/mL on average in
normotensive mice, and the inhibition efficiency is 36.94%.
On the other hand, TE decreased 62.46% circulating serotonin

Frontiers in Cardiovascular Medicine

Myxomatous changes on mitral valves
were observed in hypertensive mice,
and reversed by a parallel telotristat
ethyl administration
Myxomatous remodeling was evaluated on Movat stains
and IHC of myxomatous markers. ECM disorganization was
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FIGURE 4

Circulating serotonin level comparison across treatments in prevention (A) and reversal (B) studies. Asterisk indicates significant difference
(p < 0.05).

general, excess MMP1 was produced by mitral valves that
received A2 (Figures 5A,B). Parallel treatment with TE
lowered MMP1 level compared to corresponding Sal or A2
specimens (Figures 5A,B). Activated phenotype transformation
was significantly enhanced in mitral valves in hypertensive
mice, as suggested by plaques of strong positive α-SMA stain
(Figures 6A,B). As expected, parallel administration of TE
reduced A2-induced cell activation. TGFβ1 showed the same
trend as α-SMA, with its expression significantly increased
in hypertensive mice but reversed by TE (Figures 6A,B).
TPH1 and 5HTR2b expression levels were highly increased
in hypertensive mice, and diminished by TE administration
(Figures 7A,B). Moreover, their expression was also lowered
by TE in normotensive mice. Based on these observations,
the prevention study uncovered that ECM proteoglycans and
myxomatous markers (MMP1, α-SMA, TGFβ1, TPH1, and
5HTR2b) were overproduced in mitral valves of hypertensive
mice, and these changes were reversed by TE.

assessed by Movat stains, where collagen, proteoglycans, and
elastic fibers were colored in yellow, greenish blue, and black,
respectively. The most easily observed ECM component is
proteoglycan, as indicated by greenish blue tint throughout
the sections (Figure 5A). In addition, black elastic fibers
dominated the atrialis layer facing the left atrium. A much
more condensed blue tint appeared in mitral valves of A2treated mice, indicating that proteoglycan accumulation was
induced by A2 (Figure 6A), with less yellow (collagen fibers).
Whereas, this proteoglycan overproduction combined with
collagen fragmentation was not observed in the presence of
TE (Figure 6A). Mitral valve thickening did not occur in
short-term (4 week prevention study) A2 supplementation
(Supplementary Figure 2A).
Expression of five myxomatous markers were assessed
by IHC in mitral valves from the same animals employed
for Movat stains. Positive expression of protein markers
was stained in dark brown, indicating affected regions. In
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FIGURE 5

(A) Investigation of mitral valve ECM remodeling by Movat stain and MMP1 IHC in prevention study. Major positive IHC stains were highlighted
by circles and arrows. Scale bar on Movat images: 100 µm. Scale bar on IHC images: 50 µm. (B) Quantification of MMP1 expression determined
by total stained area in pixels that measured from 4 biological replicates in MATLAB. Asterisk indicates significant difference (p < 0.05).

FIGURE 6

(A) Investigation of mitral valve VIC activation by IHC examinations on α-SMA and TGFβ1 in prevention study. Major positive IHC stains were
highlighted by circles and arrows. Scale bar: 50 µm. (B) Quantification of their expression determined by total stained area in pixels that
measured from 4 biological replicates in MATLAB. Asterisk indicates significant difference (p < 0.05).
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FIGURE 7

(A) Investigation of local serotonin signaling in mitral valve by IHC examinations on TPH1 and 5HTR2b in prevention study. Major positive IHC
stains were highlighted by circles and arrows. Scale bar: 50 µm. (B) Quantification of their expression determined by total stained area in pixels
that measured from 4 biological replicates in MATLAB. Asterisk indicates significant difference (p < 0.05).

Myxomatous changes on mitral valves
were observed in hypertensive mice,
and reversed by a late telotristat ethyl
administration

on myxomatous proteins, mitral valves were significantly
thickened by A2, compared to those from normotensive
animals (Supplementary Figure 2B). The major finding from
the reversal study is that ECM proteoglycans and all protein
markers were overproduced in mitral valves of hypertensive
mice, and these changes were at least partially reversed by a
2-week late TE administration.

Consistently with the observations from the prevention
study, the reversal study showed that proteoglycans
accumulated in A2-treated mitral valves, as suggested by a
higher density of greenish blue stain (Figure 8A), and this
was effectively reversed by a 2-week late administration of
TE. As before, MMP1, α-SMA, TGFβ1, TPH1, and 5HTR2b
were assessed in mitral valves obtained from the reversal
study. In general, they all presented similar trends as those
observed from the prevention study. MMP1 (Figures 8A,B)
expression was higher in hypertensive than normotensive
mice, and in both cases, TE decreased MMP1 expression.
α-SMA and TGFβ1 (Figures 9A,B) levels were significantly
increased by A2, and these trends were reversed by TE.
Also in agreement with the prevention study, TPH1 and
5HTR2b (Figures 10A,B) expression levels in mitral valves
were always higher in hypertensive mice, but decreased upon
TE administration. In addition to the significant changes
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Discussion
Angiotensin II has been known to induce hypertension in
mice and its effect has been validated in several studies (24, 25).
Our goal was to employ this model as an inducer of myxomatous
disease and use it as a tool to uncover the role of serotonin
in myxomatous mitral disease. Previously, hypertension was
been successfully induced via chronic systemic A2 infusion in
mice with mitral valves presenting myxomatous changes (26).
Additional indirect evidence suggested that A2 is a contributor
to the progress of myxomatous mitral disease (27, 28). The SBP
reported for C57BL/6J at age 8–14 weeks, is 120 mmHg, (29)
which is comparable to our experimental results.
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FIGURE 8

(A) Investigation of mitral valve ECM remodeling by Movat stain and MMP1 IHC in reversal study. Major positive IHC stains were highlighted by
circles and arrows. Scale bar on Movat images: 100 µm. Scale bar on IHC images: 50 µm. (B) Quantification of MMP1 expression was
determined by total stained area in pixels that measured from 4 biological replicates in MATLAB. Asterisk indicates significant difference
(p < 0.05).

FIGURE 9

(A) Investigation of mitral valve VIC activation by IHC examinations on α-SMA and TGFβ1 in reversal study. Major positive IHC stains were
highlighted by circles and arrows. Scale bar: 50 µm. (B) Quantification of their expression determined by total stained area in pixels that
measured from 4 biological replicates in MATLAB. Asterisk indicates significant difference (p < 0.05).
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FIGURE 10

(A) Investigation of local serotonin signaling in mitral valve by IHC examinations on TPH1 and 5HTR2b in reversal study. Major positive IHC stains
were highlighted by circles and arrows. Scale bar: 50 µm. (B) Quantification of their expression determined by total stained area in pixels that
measured from 4 biological replicates in MATLAB. Asterisk indicates significant difference (p < 0.05).

It has been demonstrated that blood pressure increases
with age in mice, as it does in humans (30–32). In both
studies presented here, TE administration seemed to curb the
effect of A2 on blood pressure, while maintaining the blood
pressure of normotensive animals. Moreover, females were
more responsive to TE effect on blood pressure reduction,
which might be a consequence of higher dose of TE due to
lower body weight. Several lines of evidence demonstrated that
high levels of circulating serotonin upregulates blood pressure,
due to its contractile effect on vascular smooth muscle cells
(33, 34). This could explain why lower serotonin (due to
TE administration) counteracted A2-induced hypertension in
mice. However, this TE-induced blood pressure drop was not
observed in humans, when TE was studied as a treatment for
carcinoid syndrome (22).
Currently, there is limited evidence showing the alteration
of circulating serotonin level in hypertensive subjects. Blood
samples collected from hypertensive and normotensive human
showed no significant difference on serotonin levels (35).
Additional studies implied that the correlation between blood
serotonin and hypertension still remains controversial (36, 37).
In our work, serotonin was downregulated by TE administration
in both hypertensive and normotensive mice. The decrease in
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serotonin in hypertensive mice may be due to the interplay
between serotonin and A2, which might not happen to the
same extent in clinical systemic hypertension. It has been
suggested that serotonin level was reduced in platelets while
elevated in plasma in hypertensive mice, although the total
content in the blood remained constant (38). In agreement
with this, human studies proposed that platelet serotonin
level decreased with hypertension due to a reduced uptake
rate by serotonin transporter (39, 40). A2 administration in
rodents was previously reported to significantly promote the
level of 5-hydroxyindoleacetic acid, a serotonin metabolite (41),
indicating that A2 accelerates serotonin metabolism, which
could potentially explain the differences in serotonin levels
measured throughout our treatments groups.
In addition to A2, the alteration of circulating serotonin
in hypertensive mice could be due to myxomatous mitral
remodeling, although serotonin synthesized by heart valve
leaflets may be too low compared to the amount carried by
platelets. However, it is still debated how circulating serotonin
is affected by myxomatous changes due to variable experimental
and clinical evidence. Higher plasma serotonin level was
identified in dogs with degenerative mitral valve disease (17).
However, this is in disagreement with another study, where
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valves of hypertensive mice that received TE administration.
In this case, VIC activation in mitral valves is regulated by
serotonin, as proposed in another study (20). Along with the
overexpression of serotonin signaling proteins, TGFβ1 as well
as its receptors are elevated in myxomatous mitral valves,
as supported by several studies (5, 48). On the other hand,
TGFβ1 cooperated with mechanical stimuli and contributed
to the progress of myxomatous changes (49), consistently
with the observation of TGFβ1 increase in hypertensive mice.
Most importantly, these myxomatous changes were reversed
upon TE administration, indicating A2-induced myxomatous
degeneration is mediated by serotonin signals.
It has been proposed that serotonin signals regulate
myxomatous mitral valve degeneration and cross-talks with
multiple other signaling pathways such as TGFβ (5). There may
be two sources of serotonin acting upon heart valves, and these
are circulating serotonin from blood and locally synthesized by
heart valve cells (44). As discussed above, the exact link between
serotonin and myxomatous mitral degeneration is still missing,
although serotonin level in blood decreased with hypertensioninduced myxomatous changes in this mouse model. Local
serotonin signaling was evaluated by expression of its synthetic
enzyme (TPH1) and receptor (5HTR2b) on mitral valves. Both
proteins were increased in hypertensive mice, and at least
partially diminished due to TE administration. These findings
are supported by in vitro studies, where TPH1 and 5HTR2b
were shown upregulated in spontaneous and mechanically
induced myxomatous mitral degeneration (15, 20, 21, 50). The
overexpression of serotonin proteins by A2 indicates that the
activation of serotonin signaling along with VIC activation.
Conversely, low serotonin due to TE administration relieves
the need for receptor expression, and subsequently reduces the
requirement for an expanded serotonin signaling machinery.
This is the potential principle by which TE reverses myxomatous
changes and prevents phenotype transformation from quiescent
VICs to activated VICs.
Limitations of this experimental design include no dose
response studies, inability to deliver TE locally, among other
technical challenges. First, TE was only studied at a dose of
300 mg/kg previously validated in mice. In addition, the dose
received by each animal is slightly variable due to the changes
in body weight. Second, fluctuations in blood pressures indicate
that A2 delivery by ALZET pumps may not always have been
at a constant rate. Third, valve thicknesses were measured at
the base of the leaflets on histological sections, which relies on
perpendicular embedding of the valve leaflet. This is not only an
experimental challenge, but it also means that the free edges of
the leaflets, potentially containing most of the remodeled areas,
were not measured due to potential embedding inaccuracies.
Next, the mouse model was chosen as a basis of comparison
for future studies with genetic models, but more conclusive
experimentation is needed with larger animals. Finally, it is
unclear how TE is distributed in the bloodstream to inhibit

plasma serotonin remained unchanged between healthy dogs
and those with myxomatous mitral degeneration while platelet
serotonin was elevated in dogs with myxomatous mitral disease
and part of healthy dogs (18). On another study, both plasma
and platelet serotonin levels were unchanged in dogs with
myxomatous mitral degeneration compared to healthy ones
(19), although local serotonin in mitral valves was a wellestablished regulator of myxomatous changes (5, 18). Based
on these current observations from dogs, it seems that the
correlation of circulating serotonin and myxomatous mitral
disease is highly case- and breed-dependent, which might be
also the case in mice. More importantly, the presence of A2
amplified the inhibitory effect of TE on serotonin. To the best of
our knowledge, this is the first study identifying the synergistic
effect of A2 and TE on circulating serotonin in a hypertensive
animal model, although the changes of circulating serotonin
with hypertension and myxomatous disease were independently
studied previously.
The extent of proteoglycan stain appeared increased in
hypertensive mice, despite rodent leaflets not showing the classic
valvular architecture (42). The overproduction of proteoglycans
in myxomatous mitral valves has been frequently observed in
other animal and human studies (43–45), and this change is
marked as a characteristic of myxomatous degeneration. Along
with proteoglycan accumulation, it has been demonstrated that
elastin content is upregulated in myxomatous mitral valve
(45), whereas this was not clearly observed in this study,
potentially due to its form of diffuse fragmentation. Therefore,
we believe that myxomatous remodeling on mitral valves was
successfully initiated in hypertensive mice, and restricted by
TE administration.
The effects of serotonin, A2 and their combination on
heart valves were studied previously in mice, where both
in vivo and in vitro models were recruited (46). In their study,
either serotonin or A2 administration elevated blood pressure
and contributed to valve thickening, ECM remodeling and
myofibroblastic transformation. In addition, their combination
synergistically enhanced these changes. These evidence supports
our observations from mitral valves that received A2. Beyond
the agreement with previous findings, our study discovered
a novel strategy for prevention or reversal of myxomatous
mitral disease by selectively inhibiting peripheral serotonin.
According to the results from the current study and previous
ones, myxomatous markers are tightly regulated by peripheral
serotonin.
It has been previously reported that phenotype
transformation preferably affects the atrialis layer in the early
phase of naturally occurring myxomatous mitral degeneration
and ventricularis layer in serotonergic valves (45, 47). In
line with previous suggestions, plaques with positive α-SMA
expression were only identified in mitral valves of hypertensive
mice, with a higher incidence on the atrialis edge. However,
the area of α-SMA-positive stains was vastly reduced in mitral
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serotonin synthesis locally on valve leaflets. Drug delivery
strategies will be needed to complement our current results.
Despite these limitations, the studies presented here were able to
show that VIC phenotypic transformation, serotonin signaling
activation, ECM remodeling and TGFβ1 overexpression were
triggered by A2-induced hypertension in mice, and in turn,
these pathological changes could be reversed by inhibiting
serotonin synthesis.
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SUPPLEMENTARY FIGURE 1

Monitor of animal weight in prevention (A) and reversal (B) studies.
Asterisk indicates significant difference (p < 0.05).
SUPPLEMENTARY FIGURE 2

Comparison of mitral valve thicknesses, as at the base of the leaflets,
across treatments in prevention (A) and reversal (B) studies. Asterisk
indicates significant difference (p < 0.05).
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